China's medical products administrator granted Fujian Cosunter Pharmaceutical (SHE:300436) breakthrough therapy designation for its hepatitis B drug, according to a Monday filing with the Shenzhen Stock Exchange.
The drug, with the generic name Neracorvir, will still have to undergo registration clinical research, the filing said.
Shares fell 5% during Monday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments